Biosimilar Antibodies

Anti-CD163 (OR2805) is a human monoclonal antibody of the IgG1 subclass designed to specifically target CD163, also known as scavenger receptor cysteine-rich type 1 protein M130. This antibody exhibits potential immunomodulating and antineoplastic properties by selectively binding to CD163, which is prominently expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME). By binding to CD163, Anti-CD163 (OR2805) effectively inhibits the interaction of CD163 with its natural ligands, thereby modulating the immunosuppressive activity of TAMs and potentially enhancing antitumor immune responses. This mechanism positions Anti-CD163 (OR2805) as a valuable tool for research in cancer immunology and therapeutic development.

Abrilumab is a fully human monoclonal antibody that targets the α4β7 integrin heterodimer with high specificity. This antibody selectively binds to the α4β7 integrin, a critical molecule involved in the pathogenesis of inflammatory bowel diseases (IBD). Abrilumab is utilized primarily in research settings to investigate the underlying mechanisms and potential therapeutic interventions for IBD.

ATN-658 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting PLAUR/uPAR/CD87. This antibody is composed of a muIgG1 heavy chain and a mκ light chain, with a molecular weight of approximately 145 kDa. For experimental control purposes, Mouse IgG1 kappa, Isotype Control is recommended.

Teropavimab (3BNC117-LS) is a monoclonal antibody specifically designed for the study of HIV infection. This antibody targets the CD4-binding site of the HIV-1 envelope glycoprotein, making it a valuable tool for researchers investigating viral entry mechanisms and immune evasion strategies. Its application in HIV research provides critical insights into the development of potential therapeutic interventions.

The Anti-SLC44A4 Antibody, also known as ASG-5ME Antibody, specifically targets the SLC44A4 protein. This antibody is utilized in the development of the antibody-drug conjugate (ADC) ASG-5ME, offering potential applications in targeted cancer therapy research.

Porustobart is a monoclonal antibody specifically targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This antibody is designed for use in research studies to investigate the modulation of immune checkpoints, which are crucial for understanding immune system behavior in cancer and other diseases. Porustobart can be utilized in various experimental settings, including flow cytometry, Western blotting, and immunoprecipitation, making it a valuable tool for researchers focusing on immunology and oncology.

Ivonescimab (AK112) is a bispecific antibody targeting both PD-1 and VEGF, designed for advanced applications in cancer research. This dual-targeting mechanism facilitates the simultaneous inhibition of immune checkpoint pathways and angiogenesis, making it a valuable tool for investigating tumor microenvironment interactions and therapeutic strategies in oncology.

The Anti-Glycophorin A (type M) Antibody (6A7M) is a chimeric mouse monoclonal antibody of the IgG1, κ isotype, specifically designed to target human Glycophorin A (type M). For optimal use in experimental controls, it is recommended to utilize the Mouse IgG1 kappa Isotype Control.

Sutacimig is a humanized antibody designed to target coagulation factor 7 and TREML1. This antibody features the (H-γ4_L-κ)_(H-γ4_L-κ) isotype configuration, optimizing its specificity and functional activity in therapeutic applications. Sutacimig is primarily utilized in research focused on the modulation of blood coagulation pathways and immune response mechanisms, making it a valuable tool for studies in hematology and immunology.

Eluvixtamab is a monoclonal antibody that targets both CD3E and CD33 antigens. This dual specificity enables it to engage T cells and myeloid cells simultaneously, making it a valuable tool for research into immune cell interactions and potential therapeutic applications in diseases characterized by aberrant myeloid cell activity.

Freneslerbart is an IgG4κ monoclonal antibody specifically designed to target Felcat allergen 1, a known allergenic protein. This antibody's high specificity makes it an invaluable tool for the study and identification of Felcat allergen 1 in various research applications, including allergenicity studies and environmental monitoring of allergens.

The Anti-CYR61/CCN1 Antibody is a recombinant human monoclonal antibody produced in CHO cells, designed to specifically target CYR61/CCN1, a key regulatory protein involved in cellular processes such as proliferation, angiogenesis, and wound healing. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as the appropriate isotype control for this antibody. This product is ideal for researchers studying cellular signaling pathways influenced by CYR61/CCN1 in various biological contexts.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody that selectively targets and inhibits folate receptor-alpha (FRα), demonstrating high affinity binding. This antibody exerts growth-inhibitory effects on cells that overexpress FRα, making it a valuable tool in oncological research focused on cancers characterized by elevated levels of this receptor.

Eblasakimab, also known as ASLAN004 and CSL-334, is a human IgG4 monoclonal antibody designed to specifically bind to the interleukin 13 receptor alpha 1 (IL13RA1). This antibody is produced in CHO-K1 cells, ensuring high fidelity and stability in its expression. Eblasakimab holds significant potential for therapeutic applications in diseases mediated by the IL-13 pathway, such as asthma and other allergic disorders.

Runimotamab is a chimeric humanized antibody of the IgG1-κ isotype, designed to specifically target CD3E and HER2 receptors. This dual targeting strategy enhances the antibody's ability to mediate immune responses against cells expressing HER2, a receptor tyrosine kinase implicated in the progression of several forms of cancer, including breast and gastric cancers. Runimotamab's engagement of CD3E on T cells potentially facilitates a more direct and potent cytotoxic response, making it a valuable tool for research in cancer immunotherapy and the study of bispecific antibody mechanisms.

Zaltenibart is a chimeric humanized antibody of the IgG4κ subtype that specifically targets MASP3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and design make Zaltenibart suitable for detailed immunological research and therapeutic investigations related to the MASP3 pathway.

Iladatuzumab (MCDS0593A) is a humanized IgG1 monoclonal antibody targeting CD79B, a molecule predominantly expressed on B cells. This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A). Iladatuzumab vedotin is specifically designed for research applications in B-cell non-Hodgkin lymphoma (B-NHL), offering potential insights into therapeutic strategies for this malignancy.

Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody engineered to target the influenza A virus (IAV) with high specificity. It binds to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome. Gedivumab is an essential tool for research in IAV infection disease studies, offering potential insights into viral entry mechanisms and the development of antiviral therapies.

The Anti-GOLM1 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target GOLM1 (Golgi Membrane Protein 1). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is essential for researchers focusing on cellular and molecular studies involving the Golgi apparatus and related protein functions.

Iratumumab (MDX-060) is a humanized IgG1κ monoclonal antibody specifically targeting CD30, a cell surface antigen. This antibody effectively inhibits the proliferation of tumor cells expressing CD30. It is primarily utilized in scientific studies focused on Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), providing a valuable tool for research into the pathophysiology and potential therapeutic approaches for these malignancies.

GSK-3050002 (E-6071) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL20. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended.

Tozorakimab (MEDI-3506) is a human immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target interleukin-33 (IL-33). This antibody plays a critical role in modulating immune responses by reducing inflammation and epithelial dysfunction. Tozorakimab is primarily utilized in research focused on chronic obstructive pulmonary disease (COPD), providing a valuable tool for exploring the pathophysiology and potential therapeutic interventions for this condition.

Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody specifically designed to target CCR8, a chemokine receptor implicated in various inflammatory and immune processes. This antibody is recommended for use with Human IgG1 kappa as an isotype control to ensure specificity and accuracy in experimental applications.

Erlizumab is a humanized monoclonal antibody designed to target Integrin beta-2 (ITGB2 / CD18), offering therapeutic potential in the management of hemorrhagic shock. This antibody selectively binds to Integrin β2, a protein involved in leukocyte adhesion and migration, thereby modulating inflammatory responses critical in the pathology of hemorrhagic shock. Erlizumab provides a novel approach to modulate the immune system's response under these critical conditions.

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody designed for high selectivity toward repulsive guidance molecule A (RGMa). This antibody effectively inhibits RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, demonstrating a potent inhibitory concentration (IC50) of approximately 97 pM. Elezanumab binds to the N-terminal of RGMa, effectively blocking BMP signaling pathways and demonstrating no cross-reactivity with RGMc. It has been shown to promote both neuroregeneration and neuroprotection across various models of neuronal injury and demyelination. Importantly, Elezanumab exerts its neuroregenerative and neuroprotective effects without affecting iron metabolism, making it a targeted therapeutic option for neurological research and potential clinical applications.

Selicrelumab is an agonistic antibody targeting CD40, known to modulate the tumor microenvironment significantly. This antibody is specifically designed for use in research focused on pancreatic cancer and neoadjuvant therapies. Selicrelumab facilitates the study of CD40's role in oncologic pathways and immune responses, making it a valuable tool for advancing cancer treatment modalities.

Boserolimab (MK-5890) is a humanized agonist monoclonal antibody designed to target CD27. By binding to CD27, it delivers a costimulatory signal that significantly enhances T-cell-mediated immune responses. This antibody is pivotal for research focused on immunotherapy and the modulation of immune responses in various diseases.

CAT-2200 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-8/IL-17A. This antibody is constructed with a human IgG1 heavy chain and a human lambda light chain, exhibiting a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. CAT-2200 serves as a valuable tool in the study of immune responses related to IL-17A, offering potential applications in immunological research and therapeutic development.

The Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody specifically designed to target MST1R, a receptor tyrosine kinase implicated in various cellular processes and oncogenic pathways. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is suitable for a range of research applications, ensuring specificity and reliability in targeting MST1R for detailed biological analysis and potential therapeutic investigation.

Vadastuximab is a humanized monoclonal antibody designed to specifically target CD33, a transmembrane receptor expressed on cells predominantly in myeloid lineages. This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), notably Vadastuximab talirine. This application highlights its potential in targeted cancer therapy, particularly for the treatment of acute myeloid leukemia (AML) where CD33 is commonly overexpressed.

Otilimab (GSK 3196165) is a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody effectively neutralizes GM-CSF by inhibiting its interaction with the cell surface receptor, thereby modulating the biological activities mediated by this cytokine. Otilimab is primarily researched for its potential therapeutic applications in conditions where GM-CSF plays a key role in pathogenesis.

KHK-2866 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target human heparin-binding EGF-like growth factor (HBEGF). This antibody has a predicted molecular weight of 145 kDa. KHK-2866 is utilized in research applications to study the role of HBEGF in various biological processes and disease states, including cancer and cardiovascular diseases.

The Anti-CSF2/GM-CSF Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the cytokine CSF2, also known as granulocyte-macrophage colony-stimulating factor (GM-CSF), playing a crucial role in immune system regulation by stimulating the production of white blood cells. This antibody is comprised of a human IgG1-type heavy chain and a human lambda-type light chain, with a predicted molecular weight of 145.02 kDa. For experimental controls, it is recommended to use Human IgG1 kappa, Isotype Control, which serves as an appropriate isotype control for this antibody. This product is essential for research focused on immunology, inflammation, and potential therapeutic interventions involving GM-CSF.

Dalmitamig is a human monoclonal antibody of the IgG4κ subtype that targets both EGFR and CD28. For experiments requiring precise isotype controls, the recommended control is Human IgG4 (S228P) kappa Isotype Control, ensuring accurate assessment of antibody specificity and function.

Ivicentamab (GEN-3009) is a bispecific monoclonal antibody of the IgG1κ subtype designed to target distinct epitopes on the CD37 antigen. This antibody is specifically engineered for the study of various cancer types, providing a valuable tool for detailed cancer research investigations.

Ganitumab (AMG 479) is a recombinant human monoclonal antibody specifically targeting the human type 1 insulin-like growth factor receptor (IGF1R). This antibody exhibits high specificity and affinity for murine IGF1R, with a dissociation constant (K_D) of 0.22 nM, effectively inhibiting the interaction between murine IGF1R and its ligands, IGF1 and IGF2. Ganitumab is primarily utilized in oncological research to study the role of the IGF1R pathway in cancer progression and potential therapeutic interventions.

Exlinkibart (LVGN-6051) is a humanized IgG1κ monoclonal antibody that specifically targets TNFRSF9. This antibody has been engineered using advanced complementarity-determining region (CDR) grafting technology to enhance its specificity and binding affinity. Exlinkibart is designed for use in research studies aimed at elucidating the biological roles of TNFRSF9 and may be applicable in therapeutic development studies focusing on diseases mediated by this receptor.

The Anti-F8/Factor VIII Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets human coagulation Factor VIII (F8), a key protein in the blood clotting cascade. This antibody features a human IgG4 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on hematology, coagulation disorders, and therapeutic antibody development.

Anti-IL-13Ra2/CD213a2 is a recombinant human monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target IL-13Ra2/CD213a2. This antibody exhibits a molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in research applications focusing on the biological pathways and disease associations linked to IL-13Ra2/CD213a2.

The Anti-Spike-RBD Single Domain mAb is a recombinant alpaca monoclonal VHH-huFc antibody produced in CHO cells. This antibody exhibits high affinity and specific binding to the receptor-binding domain (RBD) of SARS-CoV-2. Its unique single-domain architecture and human Fc fusion enhance both stability and detection capabilities, making it an ideal tool for research applications focused on COVID-19 and related coronavirus studies.

Polatuzumab is a monoclonal antibody specifically designed to bind to CD79b, a protein expressed on the surface of B cells. This antibody serves as a foundational component for the creation of the antibody-drug conjugate (ADC) Polatuzumab Vedotin, which exhibits potent anti-tumor properties. This targeted approach allows for the direct delivery of cytotoxic agents to malignant cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. Polatuzumab and its derivatives are pivotal in advancing research and treatment options in oncology, particularly in the study and management of hematological malignancies.

Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1, demonstrating sustained safety and efficacy profiles in managing recurrent or metastatic cervical cancer. This therapeutic antibody shows promising potential in treating additional oncological indications, including small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma. Its mechanism involves the inhibition of the PD-1/PD-L1 pathway, a critical axis in tumor immune evasion, thereby enhancing anti-tumor immune responses. Socazolimab is under investigation for its versatility and effectiveness across a broad spectrum of cancer types.

Eldelumab (BMS-936557) is a human monoclonal antibody of the IgG1 subtype designed to selectively target and neutralize CXCL10 (IP-10). By binding to CXCL10, Eldelumab effectively inhibits CXCL10-induced calcium flux and cellular migration. This antibody is particularly useful in research focused on autoimmune and auto-inflammatory disorders, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease, providing a valuable tool for elucidating the role of CXCL10 in these conditions.

Cibotercept is a monoclonal antibody designed to target and inhibit the activity of MSTN (Myostatin), INHBA (Inhibin Beta A), and GDF11 (Growth Differentiation Factor 11). This antibody is engineered for high specificity and affinity, making it ideal for research applications focused on muscle growth, regulation, and related signaling pathways.

The Anti-SEZ6 Antibody (SC17) is a monoclonal IgG1 antibody targeting the SEZ6 protein. This antibody serves as a primary component in the development of antibody-drug conjugates (ADCs), including the specific ADC product ABBV-011. It is designed for high specificity and affinity in binding to the SEZ6 antigen, making it a valuable tool in targeted therapeutic applications.

Sotevtamab (16B5) is a humanized IgG2 monoclonal antibody specifically targeting clusterin. It acts as an inhibitor of the epithelial to mesenchymal transition (EMT), a process critical in the development and progression of cancer. This antibody is particularly useful in cancer research, providing a valuable tool for studying the role of clusterin in tumor dynamics and potential therapeutic interventions.